Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intermittent Versus Continuous Renal Replacement Therapy for Acute Renal Failure

This study has been terminated.
Sponsor:
Information provided by:
Ziekenhuis Netwerk Antwerpen (ZNA)
ClinicalTrials.gov Identifier:
NCT00322933
First received: May 5, 2006
Last updated: October 25, 2006
Last verified: April 2005
  Purpose

This multicentre SHARF4 (Stuivenberg Hospital Acute Renal Failure) study aims to investigate outcome in patients with acute renal failure (ARF), stratified according to severity of disease (SHARF score) and randomised to different treatment options.

All adult patients with a serum creatinine >2 mg/dl were included. Patients were stratified according to disease severity and those in need for RRT were randomised to intermittent (IRRT) or continuous renal replacement therapy (CRRT)


Condition Intervention
Renal Insufficiency, Acute
Renal Replacement Therapy
Procedure: renal replacement therapy (intermittent or continuous)

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Multicentre Randomised Trial of Intermittent Versus Continuous Renal Replacement Therapy for Acute Renal Failure

Further study details as provided by Ziekenhuis Netwerk Antwerpen (ZNA):

Estimated Enrollment: 1628
Study Start Date: April 2001
Estimated Study Completion Date: March 2005
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adults (>17 years)
  • having acute renal failure: serum creatinine > 2 mg/dl
  • being in need for chronic renal replacement therapy (the decision to treat conservatively or to start RRT was at the discretion of the attending physician, taking into account the rules of good clinical practice in this field)

Exclusion Criteria:

  • patients with known pre-existing chronic renal disease, defined as a serum creatinine above 1.5 mg/dl or with clearly reduced kidney size on ultrasound were excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00322933

Locations
Belgium
Robert Lins
Antwerp, Belgium, 2170
Sponsors and Collaborators
Ziekenhuis Netwerk Antwerpen (ZNA)
Investigators
Principal Investigator: Robert L Lins, MD PhD Ziekenhuis Netwerk Antwerpen (ZNA)
  More Information

Publications:
Lins R, Elseviers M, Daelemans R, Zachée P, Gheuens E, Lens S, De Broe ME. Prognostic value of a new scoring system for hospital mortality in acute renal failure. Clin Nephrol 2000;53:10-17 Lins RL, Elseviers MM, Daelemans R, Arnouts P, Billiouw JP, Couttenye M, Gheuens E, Rogiers P, Rutsaert R, Van der Niepen P, De Broe ME. Re-evaluation and modification of the Stuivenberg hospital acute renal failure (SHARF) scoring system for the prognosis of acute renal failure: an independent multicentre, prospective study. Nephrol Dial Transplant 2004;19:2282-2288

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00322933     History of Changes
Other Study ID Numbers: SHARF4
Study First Received: May 5, 2006
Last Updated: October 25, 2006
Health Authority: Belgium: Institutional Review Board

Keywords provided by Ziekenhuis Netwerk Antwerpen (ZNA):
intermittent renal replacement therapy
continuous renal replacement therapy
acute renal failure
renal recovery
mortality

Additional relevant MeSH terms:
Acute Kidney Injury
Renal Insufficiency
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on November 24, 2014